Lipad Inj. 20mg
Now Target & Treat with Confidence
Lipad 20mg (PEGylated Liposomal Doxorubicin) A GAME-CHANGER IN ONCOLOGY
Lipad (PLD) offers a targeted, effective, and safer chemotherapy option for patients with various cancers,
Abyga Tab. 250mg
Abiraterone Acetate in PAKISTAN from FDA and EU GMP certified manufacturing plant
For Metastatic Castration-Resistant Prostate Cancer; STAMPEDE trial
For Metastatic Castration-Sensitive Prostate Cancer; LATITUDE trial
Irinotecan medac inj. 100mg
Irinotecan medac – Used both as monotherapy & in combination with other drugs in first & Second line treatment of advanced and metastatic colorectal cancers.
Irinotecan combined with 5-fluorouracil, oxaliplatin and several molecularly-targeted anticancer
Temomedac Cap 20/100mg
IMPROVING PATIENT SURVIVAL RATES FOR MAELIGNANT BRAIN TUMORS
STANDARD REGIMEN FOR GBM & ASTROCYTOMAS
Median survival time for Anaplastic Astrocytoma patients treated with Temomedac® (chemotherapy): 13.6 months1
Lorelin depot Inj. 3.75mg/7.5mg/11.25mg
Sustained occupation of pituitary GnRH receptors by Leuprorelin results in desensitization and/or downregulation of receptors in the anterior pituitary, thereby suppressing gonadotrophin release and reducing testosterone release by the human testes to castrate levels.
Oxaliplatin medac 50/100/150mg
Oxaliplatin Medac (oxaliplatin for injection) is an antineoplastic agent for the treatment of colorectal cancer. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1, 2-diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.
AMGOFIL 300mcg/ml
Accelerate neutrophil recovery with AMGOFIL Chemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy.
THROMBOMAX 12MIU/1.5mg
Avoid platelet transfusions in successive chemotherapies with Thrombomax! Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions.